AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36738929
Drug: High-dose radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radiation (74 Gy)
Trial: 36739136
Drug: Genotype-guided drug
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided drug treatment (n=3342)
Trial: 36739136
Drug: All patients
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients receiving genotype-guided treatment (n=2923)
Trial: 36739258
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) and oral acetazolamide (OA) combination therapy (250mg twice daily)
Trial: 36739258
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) monotherapy
Trial: 36739285
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) or Tamoxifen + Aromatase Inhibitors (TAM-AI)
Trial: 36739285
Drug: GnRHa (Gonadotropin-Releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa (Gonadotropin-Releasing Hormone Agonists)
Trial: 36739457
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of PMVs and MMVs with radiation dose
Trial: 36739508
Drug: Weekly attack
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly attack frequency recording
Trial: 36739595
Drug: μ-opioid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: μ-opioid receptor agonists (MORAs)
Trial: 36739866
Drug: Conventional ESA
RxNorm normalized name: esafoxolaner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ESA treatment (standardized to weekly intravenous epoetin)
Trial: 36740715
Drug: chidamide +
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: chidamide + JAK inhibitor ruxolitinib
Trial: 36740814
Drug: Olorinab 50
RxNorm normalized name: Olorinab
DrugBank: Olorinab (DB14998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olorinab 50 mg
Trial: 36741122
Drug: Routine assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine assessment and effective treatment of anhedonia
Trial: 36741404
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with a live attenuated vaccine
Trial: 36742008
Drug: Curcumin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin and quercetin (CUR-QUE) oral supplement
Trial: 36744469
Drug: Active hypertension
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active hypertension treatment
Trial: 36744737
Drug: Autologous whole
RxNorm normalized name: Autologous whole blood product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous whole blood clot treatment
Trial: 36745273
Drug: Early recognition,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early recognition, monitoring, and treatment of APOs
Trial: 36745299
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with UC with CRP > 5 mg/dl
Trial: 36745299
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with UC with Fcal > 250 mg/kg
Trial: 36745299
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with IBD with CRP < 5 mg/dl
Trial: 36745299
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with IBD with Fcal < 250 mg/kg
Trial: 36745371
Drug: Roflumilast cream
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast cream 0.05%
Trial: 36745371
Drug: Roflumilast cream
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast cream 0.15% and 0.05%
Trial: 36745371
Drug: Roflumilast cream
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast cream
Trial: 36745412
Drug: Quarterly antibiotic
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quarterly antibiotic prescribing audit and feedback with peer benchmarking
Trial: 36745422
Drug: Shed-MEDS intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Shed-MEDS intervention (pharmacist- or nurse practitioner-led comprehensive medication review, deprescribing recommendations, and actions initiated in the hospital and continued in PAC)
Trial: 36745684
Drug: Fortified BEP
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fortified BEP supplements and iron-folic acid (IFA) tablets during pregnancy
Trial: 36746169
Drug: Immediate PrEP
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate PrEP (tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg daily)
Trial: 36746174
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (10 mg/kg per day for 3 days)
Trial: 36746174
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulins (2 g/kg as a single dose)
Trial: 36746334
Drug: 7-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7-day regimen of intravenous cefazolin (1 g every 12 hours) and oral clarithromycin (500 mg every 12 hours)
Trial: 36746334
Drug: Until-delivery regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Until-delivery regimen of intravenous cefazolin (1 g every 12 hours) and oral clarithromycin (500 mg every 12 hours)
Trial: 36746334
Drug: Until-delivery regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Until-delivery regimen of intravenous cefazolin and clarithromycin
Trial: 36746334
Drug: 7-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7-day regimen of intravenous cefazolin and clarithromycin
Trial: 36746385
Drug: Nelonemdaz (5,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelonemdaz (5,250 mg divided by 10 times for 5 days)
Trial: 36746510
Drug: dalutrafusp alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dalutrafusp alfa (0.3, 1, 3, 10, 20, 30, or 45 mg/kg) intravenously every 2 weeks (Q2W) up to 1 year or until progressive disease (PD) or unacceptable toxicity
Trial: 36746510
Drug: dalutrafusp alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dalutrafusp alfa (20 mg/kg and higher)
Trial: 36746510
Drug: dalutrafusp alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dalutrafusp alfa treatment
Trial: 36746739
Drug: Inactivated poliovirus
RxNorm normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliovirus vaccine (IPV) + double mutant Labile Toxin (dmLT)
Trial: 36746739
Drug: Bivalent live
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent live oral polio vaccine (bOPV)
Trial: 36746805
Drug: CRAFT (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRAFT (Cognitive Retraining and Functional Treatment)
Trial: 36746812
Drug: Intravenous antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotic treatment (Meropenem) for bronchiectasis exacerbations
Trial: 36746819
Drug: 0.1 ml
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml of 4% articaine with 1:100,000 epinephrine (4%Ar + Ep)
Trial: 36746819
Drug: 0.2 ml
RxNorm normalized name: isopropyl alcohol 0.2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 ml of 4% articaine with 1:100,000 epinephrine (4%Ar + Ep)
Trial: 36746819
Drug: 0.3 ml
RxNorm normalized name: ethanol 0.3 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 ml of 4% articaine with 1:100,000 epinephrine (4%Ar + Ep)
Trial: 36746851
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of perampanel 2, 4, or 8 mg
Trial: 36746851
Drug: Once-daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral perampanel 2 mg on Days 1-7 and 4 mg on Days 8-21
Trial: 36746922
Drug: Supplement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement of PE in statin or fibrate therapy
Trial: 36746967
Drug: Neratinib 240
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib 240 mg orally daily
Trial: 36747095
Drug: jRSAID with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: jRSAID with age at onset (AO) < 130 months and disease-modifying therapy (DMT) < 2 months
Trial: 36747095
Drug: jRSAID with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: jRSAID with age at onset (AO) < 130 months and disease-modifying therapy (DMT) > 2 months
Trial: 36747118
Drug: Pucotenlimab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pucotenlimab (3 mg/kg every 3 weeks until disease progression, intolerable toxicity, or treatment discontinuation)
Trial: 36747119
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of bupivacaine for ESPB
Trial: 36747119
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of bupivacaine for ESPB
Trial: 36747142
Drug: Psychomotor treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychomotor treatment
Trial: 36747194
Drug: Enhanced MDA
RxNorm normalized name: BK-MDA
DrugBank: BK-MDA (DB12809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced MDA with community-wide treatment followed by 2 rounds of targeted treatment to children (ages 6 months to 9 years) at 2 weeks and 4 weeks after community MDA.
Trial: 36747244
Drug: Metformin continuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin continuation during coronary angiography
Trial: 36747246
Drug: Group-based, online,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based, online, compassion-focussed therapy and breathing pattern retraining intervention for 6 weeks
Trial: 36747246
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (treatment as usual)
Trial: 36747276
Drug: Intervention (individualized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (individualized nutritional therapy + standard of care)
Trial: 36748398
Drug: Cytosine methylation
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytosine methylation of the 1F promoter of the glucocorticoid receptor
Trial: 36748723
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg) every 3 weeks for up to 35 cycles
Trial: 36749104
Drug: Ophthalmic 5%
RxNorm normalized name: natamycin ophthalmic 5% ophthalmic suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic 5% povidone-iodine
Trial: 36749131
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (oral magnesium hydroxide 15 mmol twice daily for 12 months)
Trial: 36749209
Drug: Xenon 129
RxNorm normalized name: xenon-129
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xenon 129 treatment, details on dosage and duration not available
Trial: 36749255
Drug: PBM application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBM application twice a week for 4 weeks
Trial: 36749255
Drug: Simulated PBM
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated PBM applied twice a week for 4 weeks (Control)
Trial: 38289999
Drug: Mineralocorticoid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineralocorticoid receptor antagonist
Trial: 36750134
Drug: THC (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (8 mg THC for 75 kg person)
Trial: 36750134
Drug: THC +
RxNorm normalized name: Tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: THC + CBD (8 mg THC and 24 mg CBD for 75 kg person)
Trial: 36750768
Drug: Satisfaction with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Satisfaction with treatment results measured by CQLS
Trial: 36750858
Drug: Postoperative extensive
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative extensive target volume irradiation with elevated radiation dose and concurrent chemotherapy (5 cycles of weekly TC: paclitaxel 50 mg/m2)
Trial: 36750858
Drug: Postoperative extensive
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative extensive target volume irradiation with elevated radiation dose and concurrent chemotherapy
Trial: 36750902
Drug: Inactivated COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated COVID-19 vaccines
Trial: 36750904
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (800 mg acutely and 400 mg daily for a week)
Trial: 36752055
Drug: Rapid molecular
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rapid molecular drug susceptibility assays for linezolid, bedaquiline, clofazimine, nitroimidazoles (pretomanid and delamanid), and pyrazinamide
Trial: 36752055
Drug: Sequencing assays
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequencing assays for novel and repurposed drug compounds
Trial: 36752227
Drug: TMVr with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMVr with MitraClip implant plus guideline-directed medical therapy (GDMT)
Trial: 36752714
Drug: Mindfulness-based music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based music therapy intervention
Trial: 36753281
Drug: Gefitinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib plus chemotherapy (pemetrexed with platinum)
Trial: 36753698
Drug: Darolutamide 600
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darolutamide 600 mg twice a day
Trial: 36753834
Drug: Apatinib 250
RxNorm normalized name: lapatinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 250 mg once daily and camrelizumab 200 mg once every two weeks intravenously every 28-day cycle
Trial: 36754009
Drug: Tolvaptan and
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan and Octreotide-LAR (two 20-mg i.m. injections)
Trial: 36754009
Drug: Tolvaptan and
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan and Placebo (two i.m. 0.9% saline solution injections)
Trial: 36754158
Drug: Myo-inositol, probiotics,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myo-inositol, probiotics, and micronutrient supplement (vitamins B2, B6, B12, D, zinc)
Trial: 36754158
Drug: Standard supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard supplement (folic acid, iron, calcium, iodine, β-carotene)
Trial: 36754174
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg OPT-302 + 0.5 mg ranibizumab
Trial: 36754174
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg OPT-302 + 0.5 mg ranibizumab
Trial: 36754174
Drug: Sham +
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham + 0.5 mg ranibizumab
Trial: 36755328
Drug: Continue standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue standard TNFi dosing
Trial: 36755328
Drug: Fixed longer
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed longer dosing intervals of TNFi
Trial: 36755418
Drug: Conventional (noncellular)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional (noncellular) therapies
Trial: 36756676
Drug: Enavogliflozin 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enavogliflozin 0.3 mg/day
Trial: 36756808
Drug: Quadrivalent seasonal
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent seasonal inactivated influenza vaccine
Trial: 36756899
Drug: rFVIIa (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFVIIa (recombinant activated factor VIIa; 80 μg/kg)
Trial: 36757318
Drug: Azithromycin (2-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (2-g oral dose)
Trial: 36757390
Drug: Dasatinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (50 mg)
Trial: 36757390
Drug: Dasatinib generic
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib generic (50 mg)
Trial: 36757445
Drug: Sintilimab 200
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200 mg plus DEB-TACE
Trial: 36757536
Drug: Firibastat 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firibastat 100 mg
Trial: 36757536
Drug: Firibastat 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firibastat 500 mg
Trial: 36757690
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid rectal spacer
Trial: 36757706
Drug: Consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation chemotherapy (high-dose cytarabine)
Trial: 36757755
Drug: Argatroban plus
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Argatroban plus alteplase (n=402); intravenous argatroban (100 μg/kg bolus over 3-5 minutes followed by an infusion of 1.0 μg/kg per minute for 48 hours) within 1 hour after alteplase (0.9 mg/kg; maximum dose, 90 mg; 10% as 1-minute bolus, remaining infused over 1 hour)
Trial: 36758420
Drug: farletuzumab +
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: farletuzumab + chemotherapy
Trial: 38671587
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + chemotherapy
Trial: 36758570
Drug: Colesevelam (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam (625 mg overencapsulated tablets, starting dose of two capsules twice daily for 12 days, titrated to effect during the first 5 days)
Trial: 36758612
Drug: Parenteral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral anticoagulants (92.1% of patients)
Trial: 36758612
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants (75.6% at discharge)
Trial: 36758612
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonists (6.7% at discharge)
Trial: 36759013
Drug: Neoadjuvant sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant sintilimab plus triplet chemotherapy (liposomal paclitaxel, cisplatin, and S-1) every 3 weeks for two cycles
Trial: 36759013
Drug: Neoadjuvant sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant sintilimab plus triplet chemotherapy
Trial: 36759673
Drug: T-VEC plus
RxNorm normalized name: T-Vec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: T-VEC plus neoadjuvant chemotherapy (NAC)
Trial: 36759720
Drug: Trabectedin/pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin/pegylated liposomal doxorubicin (TP) followed by platinum therapy at relapse
Trial: 36759901
Drug: Intranasal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal infusion of neural stem cells (NSCs) with nasal patches and rehabilitation therapy